Mary Szela

Ms. Mary T.
Szela is an Independent Director at Kura Oncology, Inc., a President, Chief Executive Officer & Director at TriSalus Operating Life Sciences, Inc. and a President, Chief Executive Officer & Director at TriSalus Life Sciences, Inc. She is on the Board of Directors at Absci Corp., Kura Oncology, Inc., TriSalus Operating Life Sciences, Inc., TriSalus Life Sciences, Inc., Court Appointed Special Advocates of Lake County and Sail Biomedicines Inc. Ms. Szela was previously employed as an Independent Director by Averin Capital Acquisition Corp., an Independent Director by Prometheus Biosciences, Inc., an Independent Director by Omega Therapeutics, Inc., an Independent Director by Alimera Sciences, Inc., a Chief Executive Officer & Director by Aegerion Pharmaceuticals, Inc., a Chief Executive Officer & Director by Novelion Therapeutics, Inc., an Independent Director by Coherus BioSciences, Inc., an Independent Director by Receptos, Inc., an Independent Director by Novo Nordisk A/S, a Co-Chief Executive Officer & Director by Melinta Therapeutics, Inc. /Old/, a Senior Vice President by US Pharmaceuticals, Inc., and a SVP-Global Strategic Marketing & Services by Abbott Laboratories.
She also served on the board at Senda Biosciences, Inc., Zikani Therapeutics, Inc., Suneva Medical, Inc. and Zikani Therapeutics, Inc. She received her undergraduate degree from the University of Illinois and an MBA from the University of Illinois.